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Maximilian Reiser1, Annette peters2, Fabian Bamberg1,3* & Holger Hetterich1
We aimed to investigate the association of smoking and physical exercise on ventricular function 
and structure, determined by cardiac magnetic resonance imaging (CMR), in subjects without known 
cardiovascular diseases. A total of 381 participants (median age 57 years) of the Cooperative Health 
Research in the Region of Augsburg (KORA) FF4 cohort underwent CMR. The participants’ smoking 
and sporting habits were measured by a questionnaire. physical inactivity was associated with a 
reduction of left ventricular ejection fraction (LV-EF), stroke volume, early diastolic peak filling rate and 
peak ejection rate of the left ventricle as well as right ventricular stroke volume. LV-EF was reduced in 
subjects with almost no physical activity compared to subjects with regular physical activity (68.4%, 
95%CI 66.8–70.1% vs. 70.8%, 95%CI 69.2–72.3%, p < 0,05). Smokers had lower right ventricular end-
diastolic volumes (80.6 ml/m², 95%CI 76.7–84.5 ml/m²; never-smokers: 85.5 ml/m², 95%CI 82.6–88.3 ml/
m²; p < 0.05) but higher extracellular volume fractions (ECV) and fibrosis volumes (34.3 ml, 95%CI 
32.5–36.0 ml, vs. 31.0 ml, 95%CI 29.6–32.3 ml, p < 0.01). We conclude that asymptomatic individuals 
without known cardiovascular diseases show differences in cardiac function and structure depending 
on their physical activity and smoking habits. this underlines the importance of prevention and health 
education.
Deaths due to cardiovascular disease increased by 12.5% globally between 2005 and 20151. Smoking and physical 
inactivity are among the main modifiable risk factors2–4. In several clinical and population-based studies, smok-
ing and physical inactivity were independently associated with advanced cardiovascular disease such as heart fail-
ure, myocardial infarction and stroke as well as cardiovascular mortality5–12. The prevalence of smoking declined 
in the last 25 years, but still about 21% of men and 6% of women worldwide were smoking in 201510. More than 
35% of adults have a sedentary life style with low physical activity10.
Some studies have also linked smoking and physical inactivity to reduced myocardial function and reduced 
ventricular mass13–16. However, there is only limited data on the association of smoking and physical inactivity 
on subclinical cardiovascular changes in asymptomatic individuals without a history of cardiovascular disease. 
Even less data is available about the influence of cardiac risk factors on diffuse myocardial fibrosis or myocardial 
scarring in asymptomatic individuals.
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Cardiac magnetic resonance imaging (CMR) is the standard of reference for the evaluation of right ventricular 
function and is less patient- and investigator-depended than echocardiography concerning left ventricular struc-
ture and function17–19. Furthermore, it allows to evaluate myocardial scarring and diffuse fibrosis20.
Thus, we aimed to investigate if smoking and physical inactivity are associated with changes in cardiac struc-
ture and function as determined by CMR in asymptomatic individuals without known cardiovascular diseases.
We hypothesized that smoking and physical inactivity are independent risk factors for elevated left and right 
ventricular mass, decreased left and right ventricular function and increased amounts of myocardial fibrosis and 
scarring.
Results
Study population. Out of the 400 participants in our sub-study, a total of 381 participants were included in 
the analysis. Nineteen examinations had to be excluded because for poor image quality or missing left ventricular 
data. The right ventricular data was available in 337 subjects. In 35 cases, data were incomplete due to software 
problems during the MRI scan or because the examination was aborted by the study participant. For 28 subjects, 
short axis images did not completely include the basal part of the right ventricle and were therefore excluded from 
the final evaluation. Data of 260 subjects were included in the calculation of extracellular volume fraction (ECV) 
and 257 subjects in the fibrosis calculation, the others had to be excluded due to artifacts, incomplete measure-
ments or missing haematocrit levels. In 368 subjects, Late Gadolinium Enhancement (LGE) measurements could 
be analysed – 32 examinations had to be discarded due to missing data or poor image quality. Baseline charac-
teristics of the study population are shown in Table 1. The study population consisted of 162/381 (43%) women 
and 219/381 (58%) men. Diabetes and hypertension were found in 49/381 (13%) and 127/381 (33%) of subjects, 
respectively. In general men had a more pronounced cardiovascular risk profile. The majority of participants 
reported regular physical activity of at least 1 h/week (227/381, 60%). A minority were active smokers (76/381, 
20%), while most participants were former or never smokers (167/381, 44% and 138/381, 36%). Men were more 
often smokers or ex-smokers (148/381, 68%) and physically inactive (65/381, 30%) compared to women (95/381, 
59% and 34/381, 21%, respectively). Medication included antihypertensive drugs (94/381, 24.6%), lipid-lowering 
(40/381, 10.5%) and antidiabetic medication (29/381, 7.6%).
Women Men
N = 162 N = 219
Age (years) 58 (48; 64) 56 (49; 64)
Smoking status
Never-smoker 67 (41.4%) 71 (32.4%)
Ex-smoker 60 (37.0%) 107 (48.9%)
Current smoker 35 (21.6%) 41 (18.7%)
Smoking Pack Years 1.1 (0; 11.7) 4.5 (0; 26.0)
Physical activity
Regular >2 h/week 45 (27.8%) 64 (29.2%)
Regular 1 h/week 58 (35.8%) 60 (27.4%)
Irregular 1 h/week 25 (15.4%) 30 (13.7%)
(Almost) no activity 34 (21.0%) 65 (29.7%)
Body mass index (kg/m²) 26.8 (23.1; 30.9)
27.9 (25.3; 
30.7)
Body surface area (m2) 1.8 (1.7; 1.9) 2.1 (2.0; 2.2)
Systolic blood pressure (mmHg) 113 (103; 122) 126 (115; 136)
Diastolic blood pressure (mmHg) 72 (66; 77) 78 (71; 83)
Hypertension 46 (28.4%) 81 (37.0%)
Diabetes status
Non-Diabetics 113 (69.8%) 119 (54.3%)
Pre-Diabetics 36 (22.2%) 64 (29.2%)
Diabetics 13 (8.0%) 36 (16.4%)
HDL-C (mg/dl) 68 (57; 82) 54 (45; 64)
LDL-C (mg/dl) 134 (112; 157) 140 (117; 162)
TG (mg/dl) 95 (68; 121) 122 (85; 186)
Antihypertensive medication 44 (27.2%) 50 (22.8%)
Lipid-lowering medication 18 (11.1%) 22 (10.0%)
Antidiabetic medication 11 (6.8%) 8.2%)
Table 1. Baseline characteristics of the study sample (N = 381). Data are given as number (percentage) 
or median (25th and 75th percentile). HDL-C, high-density-lipoprotein cholesterol; LDL-C, low-density-
lipoprotein cholesterol; TG, triglycerides.
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cardiac function and structure. Overall, mean left and right ventricular parameters of the study popu-
lation were within normal limits (left ventricular end-systolic volume (LV-ESV): 40.7 ± 18.1 ml, left ventricu-
lar end-diastolic volume (LV-EDV): 129.1 ± 32.9 ml, left ventricular ejection fraction (LV-EF): 69.2 ± 8.2%, left 
ventricular stroke volume (LV-SV): 88.3 ± 20.7 ml, left ventricular (LV) myocardial mass: 140.7 ± 35.0 g, right 
ventricular end-diastolic volume (RV-EDV): 165.5 ± 39.8 ml, right ventricular end-systolic volume (RV-ESV): 
79.1 ± 25.9 ml, right ventricular stroke volume (RV-SV): 86.4 ± 19.5 ml and right ventricular ejection fraction 
(RV-EF): 52.8 ± 7.0%) with some subjects with reduced LV-EF (8/381, 2%) or RV-EF (31/381, 8%) or increased 
LV volumes (5/381, 1%) or RV volumes (15/381, 4%)21. A total number of 11 individuals (2.9%) showed LGE and 
mean ECV and fibrosis volume were 0.24 ± 0.03% and 31.8 ± 8.2%, respectively.
Association of physical inactivity with cardiac function and structure. Multivariable linear regres-
sion analysis revealed that physical inactivity was associated with a decrease in LV-SV, LV-EF, Peak Ejection 
Rate (PER) and early diastolic filling rate (PFR1). There was a decrease in LV-EF from subjects with regular 
2 h exercise per week (70.8%, 95%-CI 69.2–72.3%) to subjects with almost no exercise (68.4%, 95%-CI 66.8–
70.1%) (p = 0.044). All LV-EF values of the different physical activity groups are displayed in Fig. 1. LV-SV was 
lower in the inactive group (44.1 ml, 95%-CI 42.3–46 ml) compared to the most active group (47.5 ml, 95%-CI 
45.8–49.3 ml) (p = 0.009). The inactive group had the lowest PER (335.8 ml/s, 95%-CI −361.2–310.4 ml/s) 
while the most active group had the highest PER (374.6 ml/s, 95%-CI −398.7–−350.5 ml/s) (p = 0.033). The 
myocardial relaxation measured by PFR1 was significantly higher in the most active group (254.2 ml/s, 95%-CI 
234.4–274.0 ml/s) compared to the inactive group (204.8 ml/s, 95%-CI 183.9–225.7 ml/s) (p = 0.001). There were 
no significant associations between physical inactivity and LV-EDV, LV-ESV, late diastolic filling rate (PFR2) or 
myocardial mass (Table 2). RV-SV was significantly lower in the inactive group (43.6 ml, 95%CI 41.8–45.4 ml) 
compared to the most active group (46.6 ml, 95%CI 44.9–48.4 ml) (p = 0.020). There were no significant associa-
tions between physical inactivity and RV-EDV, RV-ESV or RV-EF (Table 3) or between physical activity and the 
amount of LGE or fibrosis volume and ECV (Table 4).
Association of smoking status with cardiac function and structure. There were no significant 
associations between smoking status and left ventricular function (Table 5). However, there was a tendency of 
increased LV mass in current smokers (145.2 ml 95%-CI 139.8–150.7 ml) compared to never-smokers (139.6 ml, 
95%-CI 135.5–143.6 ml) (p = 0.102).
RV-EDV was significantly lower in current smokers (80.6 ml, 95% CI 76.7–84.5 ml) than in never-smokers 
(85.5 ml, 95% CI 82.6–88.3 ml) (p = 0.048). Smoking status showed no significant associations with RV-ESV, 
RV-SV and RV-EF (Table 6).
Smokers showed significantly higher ECV (0.25%, 95%CI 0.24–0.26% vs. 0.24%, 95%CI 0.24–0.26%, p < 0.01) 
and fibrosis volumes (34.3 ml, 95%CI 32.5–36.0 ml, vs. 31.0 ml, 95%CI 29.6–32.3 ml, p < 0.01) (Table 7).
Discussion
In this cross-sectional study, we examined the association of physical inactivity and smoking habits on cardiac 
function and structure as assessed by CMR in subjects without known cardiovascular disease. Parameters for 
left and right ventricular function were within normal limits for the vast majority of participants. However, we 
found that physical inactivity is associated with a reduction of LV and RV systolic and LV diastolic function. 
Furthermore, smoking was associated with a reduction of RV-EDV and with elevated ECV and fibrosis volumes.
These findings are in line with results of the Multi-Ethnic Study of Atherosclerosis (MESA)16. In MESA as well 
as in our study, LV-SV increased with exercise. In contrast to MESA, we have also found a positive effect on LV-EF. 
Potentially these results could be explained by differences in the assessment of physical activity or differences in 
the ethnicities of the study (the KORA population being completely Caucasian). Furthermore, we used a 3-Tesla 
MRI system, which offers an increased signal-to-noise-ratio and contrast-to-noise-ratio compared to 1.5-Tesla22.
Figure 1. Observed ejection fraction in different groups of physical activity demonstrated by box plots 
(box = interquartile range, horizontal line = median, whiskers = lower and upper adjacent values), (*p < 0.05, 
reference category = “regular 2 h/week”). Subjects with regular physical activity 2 h/week showed significantly 
higher LV-EF than subjects with (almost) no physical activity.
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Levy et al. showed that older and untrained subjects had a lower PFR123. This correlates with our results, 
where subjects with the highest physical activity per week had the highest PFR1. In our study subjects with more 
than 2 hours of physical activity per week had the highest PER, as was already demonstrated by Stratton et al.24, 
where untrained men had lower PER.
Our study shows that physical activity has a significant positive effect on RV-SV. Regular physical activity also 
positively influenced RV-EDV and RV-EF, but these results were not significant. This is in line with the results 
of Aaron et al. in the MESA trial15. The higher RV-SV could be caused by hypertrophy of cardiomyocytes due to 
physical activity, causing higher left and right SV25.
In former studies, subjects with higher physical activity rates showed no difference in cardiac fibrosis vol-
umes26, but more LGE27, while in our study physical activity had no significant effect on fibrosis volumes, ECV or 
LGE. As physical activity influences cardiac function and hypertrophy, fibrosis and ECV could also be affected, 
whereas presence of LGE should not differ between subjects with more or less physical activity. These partly dif-
fering results need more research in the future.
We observed a trend towards increased left ventricular mass in smokers, a result that is in line with MESA and 
other studies16,28. In contrast, the LARGE study found a smaller left ventricular mass in smokers, maybe due to 
the special cohort of the LARGE study, which comprised only healthy young men29.
Analogous to the MESA study, RV-EDV was lower in smokers30–32. Cigarette smoke includes several toxic 
substances that cause aging of cardiomyocytes and thus reduced compliance of the right ventricle33. Smoking can 
lead to chronic obstructive pulmonary disease, which causes hyperinflation of the lungs32. Both mechanisms can 
thus reduce RV filling.
We were able to demonstrate that current smokers had significantly higher ECV and fibrosis volumes com-
pared to non-smokers, which can be explained by oxidative stress and inflammation causing cardiac remodeling 
in smokers34. In MESA, smokers also had more LGE35, whereas in our study smokers had less LGE, but this result 
was not significant. It is known that smokers are more vulnerable concerning coronary heart disease so it could 
be expected that smokers and ex-smokers show more LGE than never-smokers. This, too, needs further research 
with larger cohorts.
Limitations and strengths of the study. As this is a cross-sectional study, we can only show correlations; 
it is not possible to draw conclusions about causations. As opposed to the LARGE study (young white males) or 









N = 109 N = 118 N = 55 N = 99
End-diastolic volume/BSA (ml/m2) 67.9 (65.2; 70.6) 65.6 (63.1; 68.2) 66.4 (62.6; 70.2) 65.0 (62.2; 67.9)
End-systolic volume/BSA (ml/m2) 20.3 (18.7; 21.9) 21.0 (19.5; 22.5) 21.1 (18.9; 23.4) 21.0 (19.3; 22.7)
Stroke volume/BSA (ml/m2) 47.5 (45.8; 49.3) 44.6 (43.0; 46.3)* 45.3 (42.9; 47.7) 44.1 (42.3; 46.0)**
Ejection Fraction (%) 70.8 (69.2; 72.3) 68.7 (67.3; 70.2) 68.5 (66.4; 70.7) 68.4 (66.8; 70.1)*
Myocardial mass, diastolic (g) 143.6 (139.0; 148.3) 138.6 (134.2; 143.0) 140.8 (134.3; 147.3) 140.0 (135.1; 144.9)
Myocardial mass, systolic (g) 146.6 (141.7; 151.4) 141.6 (137; 146.2) 141.3 (134.5; 148.1) 142.7 (137.6; 147.8)
Peak systolic ejection rate (ml/s) −374.6 (−398.7; −350.5) −346.0 (−368.8; −323.1) −363.8 (−397.8; −329.8) −335.8 (−361.2; −310.4)*
Early diastolic filling rate (ml/s) 254.2 (234.4; 274.0) 218.0 (199.2; 236.7)** 223.5 (195.6; 251.5) 204.8 (183.9; 225.7)**
Late diastolic filling rate (ml/s) 253.2 (226.7; 279.7) 237.8 (212.7; 262.9) 237.4 (199.9; 274.8) 217.9 (189.9; 245.8)
Table 2. Physical activity and left ventricular volumes, myocardial mass and function (N = 381). Data are 
adjusted predicted means and 95% confidence intervals after linear regression adjusted for age, sex, body mass 
index, systolic blood pressure, diastolic blood pressure, diabetes mellitus; BSA, body surface area. **p < 0.01, 










N = 97 N = 107 N = 47 N = 86
End-diastolic volume/BSA (ml/m2) 87.4 (84.1; 90.6) 83.1 (80.0; 86.2) 86.1 (81.4; 90.8) 83.2 (79.7; 86.7)
End-systolic volume/BSA (ml/m2) 40.8 (38.5; 43.0) 40.3 (38.2; 42.4) 41.2 (38.0; 44.4) 39.6 (37.3; 42.0)
Stroke volume/BSA (ml/m2) 46.6 (44.9; 48.4) 42.9 (41.3; 44.5)** 44.9 (42.4; 47.4) 43.6 (41.8; 45.4)*
Ejection Fraction (%) 53.8 (52.5; 55.1) 52.0 (50.8; 53.3) 52.9 (51.0; 54.8) 52.7 (51.3; 54.1)
Table 3. Physical activity and right ventricular volumes and function (N = 337). Data are adjusted predicted 
means and 95% confidence intervals after linear regression adjusted for age, sex, body mass index, systolic blood 
pressure, diastolic blood pressure, diabetes mellitus; BSA = body surface area. **p < 0.01, *p < 0.05, §Reference 
category = “regular 2 h/week”.
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females. As a result, our cohort is better suited for the population in Germany than the LARGE or MESA cohorts. 
Our results are in general in line with the results of other large cohort studies examining subclinical cardiovascu-
lar changes depending on risk factors.
Smoking status was assessed via questionnaire, so there was no biochemical confirmation of smoking status. 
Whereas subjects with known cardiovascular diseases were excluded from the KORA study, participants with 
known pulmonary diseases that could affect the right ventricle, were not excluded. Another limitation is that the 
subjects’ amount of physical activity was based on an interview and not validated via ergometry, resting heart rate 
or electronic activity trackers like wristbands.
The differences between the examined groups were small and most probably have no clinical significance but 
may represent early manifestations of potentially progressive disease.
Most studies about the impact of cardiac risk factors used echocardiography, for example the Framingham 
Study. Echocardiography is a widely available method, it is fast, cost-effective and does not use radiation. 
Unfortunately, echocardiography is more dependent on the patient’s constitution, depending on the patient’s 
acoustic windows, and has quite a high inter-observer variability36. Especially when measuring LV-EF using the 
Simpson method, echocardiography has its limitations because frequently the endocardial contours are often 
not clearly visible when not using contrast agents17. Whereas cardiac magnetic resonance imaging (CMR) has 










ECV (%) 0.24 (0.23; 0.25) 0.24 (0.24; 0.25) 0.25 (0.24; 0.26) 0.24 (0.24; 0.25)
Fibrosis volume (ml) 32.6 (31.0; 34.1) 31.2 (29.8; 32.6) 32.3 (30.2; 34.5) 31.4 (29.6; 33.1)
LGE# (%) 3.8 (0.1; 7.5) 2.0 (−0.8; 4.8) 2.1 (−2.0; 6.2) 3.2 (0.1; 6.2)
Table 4. Physical activity and left ventricular scarring and fibrosis. Data are adjusted predicted means or 
#proportions and 95% confidence intervals after linear regression or #logistic regression adjusted for age, sex, 
body mass index, systolic blood pressure, diastolic blood pressure, diabetes mellitus; ECV = extracellular 
volume fraction; LGE = Late Gadolinium Enhancement. All p > 0.05. §Reference category = “regular >2 h/
week”.
Smoking status
Never-smoker§ Ex-smoker Current smoker
N = 138 N = 167 N = 76
End-diastolic volume/BSA (ml/m2) 66.1 (63.7; 68.4) 67.1 (64.9; 69.2) 64.7 (61.6; 67.9)
End-systolic volume/BSA (ml/m2) 21.1 (19.7; 22.5) 20.9 (19.6; 22.2) 20.2 (18.3; 22.0)
Stroke volume/BSA (ml/m2) 45.0 (43.4; 46.5) 46.2 (44.8; 47.6) 44.6 (42.5; 46.6)
Ejection Fraction (%) 68.8 (67.4; 70.1) 69.5 (68.3; 70.8) 69.3 (67.5; 71.1)
Myocardial mass, diastolic (g) 139.6 (135.5; 143.6) 139.6 (135.9; 143.3) 145.2 (139.8; 150.7)
Myocardial mass, systolic (g) 142.2 (138.0; 146.5) 141.7 (137.8; 145.5) 148.7 (143.0; 154.4)
Peak systolic ejection rate (ml/s) −353.4 (−374.6; −332.3) −358.7 (−377.9; −339.4) −345.0 (−373.5; −316.5)
Early diastolic filling rate (ml/s) 226.8 (209.3; 244.4) 228.9 (213.0; 244.9) 216.7 (193.1; 240.3)
Late diastolic filling rate (ml/s) 240.2 (217.0; 263.4) 241.3 (220.2; 262.4) 221.7 (190.5; 252.9)
Table 5. Smoking status and left ventricular myocardial mass and function (N = 381). Data are adjusted 
predicted means and 95% confidence intervals after linear regression adjusted for age, sex, body mass index, 
systolic blood pressure, diastolic blood pressure, diabetes mellitus; BSA = body surface area. All p > 0.05. 
§Reference category = “never-smoker”.
Smoking status
Never-smoker§ Ex-smoker Current smoker
N = 121 N = 149 N = 67
End-diastolic volume/BSA (ml/m2) 85.5 (82.6; 88.3) 86.1 (83.5; 88.7) 80.6 (76.7; 84.5)*
End-systolic volume/BSA (ml/m2) 41.3 (39.4; 43.2) 40.6 (38.9; 42.4) 38.1 (35.5; 40.7)
Stroke volume/BSA (ml/m2) 44.2 (42.7; 45.7) 45.5 (44.1; 46.9) 42.5 (40.5; 44.6)
Ejection Fraction (%) 52.1 (50.9; 53.3) 53.2 (52.2; 54.3) 53.4 (51.8; 54.9)
Table 6. Smoking status and right ventricular function (N = 337). Data are adjusted predicted means and 
95% confidence intervals after linear regression adjusted for age, sex, body mass index, systolic blood pressure, 
diastolic blood pressure, diabetes mellitus; BSA = body surface area. *p < 0.05, §reference category = “never-
smoker”.
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endocardium and blood in order to properly measure endocardial contours to measure left ventricular volumes 
and calculate left ventricular ejection fraction18,37. For left ventricular hypertrophy, CMR has higher sensitivity 
rates than echocardiography38. Furthermore, it was shown that CMR has higher reproducibility rates in right 
ventricular parameters39,40. CMR can therefore be called the standard of reference for detecting the smallest, but 
still significant changes in cardiac function and mass parameters19.
conclusions
Using CMR, our study showed that in subjects without a history of cardiovascular diseases, parameters of left and 
right ventricular function increase with physical activity and decrease with smoking. In addition, we were found 
increases in ECV and fibrosis volumes in smokers. These results underline once more the importance of preven-
tion and health education in order to prevent subclinical and in hereafter symptomatic cardiovascular changes.
Methods
Study population. Study participants were recruited from the second follow-up (FF4) of the popula-
tion-based KORA (“Kooperative Gesundheitsforschung in der Region Augsburg”, Cooperative Health research 
in the region of Augsburg) S4 cohort. S4 is a health survey (1999–2001) comprising 4,261 individuals, 25 to 
74 years of age, in the region of Augsburg in the south of Germany. The first follow-up (F4) was conducted 
between 2006 and 2008 with 3,080 participants and the second follow-up (FF4) took place in 2013/2014 with 
2,279 participants41.
The current study population was drawn from a sub-study that aimed at examining MRI-derived subclinical 
cardiovascular disease burden in diabetics, pre-diabetics and controls without a history of cardiovascular dis-
ease42. For this study, subjects were recruited from the KORA FF4 follow-up. Exclusion criteria were: age >72 
years, subjects with validated/self-reported stroke, myocardial infarction or revascularization, subjects with a 
cardiac pacemaker or implantable defibrillator, cerebral aneurysm clip, neural stimulator, any type of ear implant, 
ocular foreign body (e.g. metal shavings), any implanted device (e.g. insulin pump, drug infusion device), preg-
nant or breast feeding female subjects, claustrophobia, known allergy against gadolinium compounds and serum 
creatinine ≥1.3 mg/dl. The inclusion criteria were: willingness to undergo whole-body MRI and qualification in 
the diabetics, prediabetics or control group according to the World Health Organization criteria43. In total, 400 
subjects aged 38–72 years were included in this study. The study was approved by the institutional review board 
of the Ludwig-Maximilians-University, Munich, and all participants provided written informed consent42. All 
methods were performed in accordance with the relevant guidelines and regulations.
MRi examination and evaluation. All images were obtained with the same 3-Tesla MR system (Magnetom 
Skyra, Siemens Healthcare, Erlangen Germany) in the Institute of Clinical Radiology of the Ludwig-Maximilian 
University Hospital in Munich. Imaging was performed using an 18-channel body coil in combination with the 
table-mounted spine matrix coil. The MRI examination was performed within three months after the FF4 visit at 
the study center. The protocol comprised imaging of the neurocranium, the carotid vessels, liver and whole-body 
fat imaging as well as cardiac imaging. Total acquisition time was approximately one hour. The full protocol is 
shown in Supplementary Table S1.
cardiac function analysis. Left ventricular function was assessed using cine-steady state free precession 
sequences which were acquired in four chamber view and short axis stack with 10 slices and 25 phases using the 
following parameters: slice thickness 8 mm, in-plane voxel size 1.5 × 1.5 mm², field of view 297 × 360 mm², matrix 
240 × 160, repetition time 29.97 ms, echo time 1.46 ms, flip angle 63°.
Evaluation of cardiac function parameters was performed using a dedicated software package (cvi42, Version 
4.1.5(190), Circle Cardiovascular Imaging Inc., Calgary, Canada). The left ventricular short-axis and four cham-
ber view images were analyzed semi-automatically. The reading was performed according to standardized 
post-processing guidelines of the Society for Cardiovascular Magnetic Resonance44 by two readers blinded to any 
information regarding the subjects’ risk factors and clinical status. After automatic contouring of the endo- and 
epicardial contours, the outlines were corrected manually, if necessary. The papillary muscles were excluded from 
the myocardial mass and included in the ventricular volumes. The position of end-diastolic and end-systolic 
phase were chosen automatically by the software. The derived parameters were: end-systolic volume (LV-ESV), 
end-diastolic volume (LV-EDV), stroke volume (LV-SV), ejection fraction (LV-EF), systolic and diastolic myocar-
dial mass, cardiac output, and left ventricular wall thickness. An example of the LV contouring is given in Fig. 2. 
Furthermore, left ventricular filling and ejection rates were determined based on the results of the left ventricular 
Smoking status
Never-smoker§ Ex-smoker Current smoker
ECV (%) 0.24 (0.23; 0.24) 0.24 (0.23; 0.24) 0.25 (0.24; 0.26)**
Fibrosis volume (ml) 31.0 (29.6; 32.3) 31.3 (30.0; 32.5) 34.3 (32.5; 36.0)**
LGE (%)# 3.0 (0.2; 5.8) 3.9 (1.3; 6.4) 0.6 (−3.2; 4.5)
Table 7. Smoking status and left ventricular scarring and fibrosis. Data are adjusted predicted means or 
#proportions and 95% confidence intervals after linear regression or #logistic regression adjusted for age, sex, 
body mass index, systolic blood pressure, diastolic blood pressure, diabetes mellitus; ECV = extracellular 
volume fraction; LGE = Late Gadolinium Enhancement. **p < 0.01. §Reference category = “never-smoker”.
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volumetry using an in-house software (pyHeart). Measured parameters were: the peak ejection rate (PER), the 
peak filling rate of the early diastole (PFR1), the peak filling rate of the late diastole (PFR2) and the delay time 
between early and late diastolic fillings.
Right ventricular volumes and function were analyzed by manual tracking of the endocardial contour on 
short-axis and manual detection of the apex and tricuspid valve on four chamber view images according to cur-
rent guidelines44. The largest and smallest right ventricular volume were defined as end-systolic and end-diastolic 
phase. Papillary muscles were included in the ventricular volume. Parameters included: end-diastolic (RV-EDV) 
and end-systolic volume (RV-ESV), stroke volume (RV-SV), cardiac output, ejection fraction (RV-EF).
Late gadolinium enhancement (LGE) sequences were acquired 10 minutes after administration of gadopen-
tate dimeglumine (0,2 mmol/kg, Gadovist, Bayer Healthcare, Berlin, Germany) as Fast Low Angle Shot (FLASH) 
inversion recovery sequences with slice thickness 8 mm, FOV 300 × 360 mm, Matrix 256 × 140, TR 700–1000 ms, 
TE 1.55 ms and FA 20–55°. Analysis of late gadolinium enhancement (LGE) was performed by two experi-
enced readers using the same software also used for the cardiac function analysis (cvi42; Circle Cardiovascular 
Imaging). In case of discrepancy, a consensus reading was performed. The presence and distribution pattern 
(subendocardial, midmyocardial, and epicardial) of LGE was documented using the AHA 17-segment model45.
For measuring myocardial fibrosis, T1 ECG-gated steady-state free-precession-based modified Look-Locker 
inversion-recovery (MOLLI) sequences with 5(3)3 pattern (acquiring 5 images after the first inversion, followed 
by a 3 heartbeat pause and then again 3 images after the second inversion) were acquired pre- and 10 minutes 
post contrast. These sequences were acquired on short axis at the mid-ventricular and basal short-axis plane 
(segments 1–12) with the following parameters:: Slice thickness 8 mm, spatial resolution: 1.5 × 1.5 mm2, acquired 
voxel size: 2.25 × 1.5 mm2, FOV: 323 × 380 mm using a 256 × 144 mm matrix, TE: 1.1, TI: 100–3500 with a 35° 
flip angle. T1 relaxation times were calculated per segment (1–12 of the 17 segments of AHA classification). The 
inner and outer contour of the left ventricular myocardium was segmented following recommendations46 to omit 
influence of surrounding fat or blood by two blinded readers. Segments with obvious artifacts or presence of LGE 
were discarded. Another region of interest was placed in the blood volume. ECV as a measure of the amount of 
extracellular matrix was calculated from the T1 relaxation times pre and post contrast by taking into account the 
haematocrit. Fibrosis volume was derived using the following formula:
•	 ΔR1myocardium = 1/T1myo-post − 1/T1myo-pre
•	 ΔR1 blood = 1/T1blood-post − 1/T1blood-pre
•	 Myocardial partition coefficient (λ)  = (ΔR1myocardium/ΔR1 blood)
•	 ECV =  (1 − haematocrit level) × λ
•	 Fibrosis volume = ECV*LVmass/myocardial density [myocardial density = 1.05 g/mL]
Figure 2. Evaluation of left ventricular function and structure. Basal (a), mid-ventricular (b), apical (c) short 
axis images and 4-chamber-view (d). LV = left ventricle; RV = right ventricle; LA = left atrium; RA = right 
atrium. Green lines indicate the epicardial contour, red/orange lines the endocardial contour. The blue lines 
indicate the tagging of the left ventricle on the 4-chamber-view.
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Assessment of smoking habits, physical activity and covariates. Smoking habits and physical 
activity of the subjects were measured in a standardized interview during the FF4 follow-up at the KORA study 
center. Physical activity was scaled as follows: Physical activity regularly more than 2 hours per week (group 1), 
regularly one hour per week (group 2), irregularly one hour per week (group 3), almost no activity (group 4). For 
smoking the scaling was: smoker, ex-smoker, never-smoker. Subjects were classified as smokers if they reported 
current regular or sporadic cigarette smoking.
Several co-variates were measured in the KORA FF4 study center by standardized interview, basic health 
examinations and laboratory analyses. They comprised: age (years), sex (male, female), body mass index (BMI, 
calculated as weight divided by squared height, kg/m²), waist circumference, body surface area, systolic and 
diastolic blood pressure, diabetes status (non-diabetics, pre-diabetics, diabetics), intake of antihypertensive, 
lipid-lowering or antidiabetic medication. Laboratory measurements including HbA1c, glucose, total cholesterol, 
high and low density lipoprotein and triglycerides were performed according to KORA standards47. Blood pres-
sure was measured three times at the right arm of seated participants after an at least five-minute resting period. 
The mean of the second and third measurement was used for the analyses. Arterial hypertension was defined 
as increased systolic blood pressure (≥140 mmHg) and/or increased diastolic blood pressure (≥90 mmHg) or 
use of antihypertensive medication under awareness of having hypertension according to 2003 World Health 
Organization / International Society of Hypertension criteria48.
Statistical analyses. Baseline characteristics of the study sample were separately described for women and 
men by median and interquartile range for continuous variables and absolute numbers and percent values for 
categorical variables.
Associations of physical inactivity and smoking (risk factors = independent variables) with left and right ven-
tricular structure and function parameters (outcomes = dependent variables) were investigated by calculating 
adjusted predicted outcome means or proportions with 95% confidence intervals by using average co-variable 
values after separated linear or logistic regression models for each risk factor and each outcome. Adjustments 
were made for age, sex, body mass index, systolic and diastolic blood pressure as well as diabetes mellitus. Physical 
inactivity and smoking status were treated as factor variables and each predicted mean was compared with its 
reference category of regular 2 hours activity per week or never smoking status, respectively. The p-value from 
t-test of the corresponding β-coefficient from the linear regression model was used to evaluate outcome differ-
ences between risk factor groups. Normal distributions of predicted residuals were tested visually. In addition, 
observed differences of LV-EF between physical activity categories were presented by box plots providing group 
medians, interquartile ranges and lower and upper adjacent values. All analyses were additionally adjusted for 
sampling weights considering differences in age, sex and diabetes status between the study sample (n = 400) and 
the entire KORA cohort (n = 2279, median age = 60 years, 48% men, 15% participants with diabetes) yielding 
no substantially changed findings. A p-value of <0.05 was considered statistically significant. Statistical analyses 
were performed using Stata 14.1 (Stata Corporation, College Station, TX, U.S.A.).
Data availability
All data are available on the KORA.PASST platform, accessible by contacting the Helmholtz Centre, Munich. 
Additional information is shown in the appendix.
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